Plné znění - 2/2008 Sb. m. s.

Ministerstvo xxxxxxxxxxxx xxxx xxxxxxx, xx xxx 16. xxxxxxxxx 2007 bylo xxxxxxxxxx xxxxxxxxx XXXXXX, depozitářem Xxxxxxxxxxx xxxxxx proti xxxxxxx ve xxxxxx¹⁾, xxxxxxxx xxxxxxxxx xxxxxx xxxxx Přílohy I - Xxxxxxx zakázaných látek x xxxxx xxxxxxx.

Xxxxxxx X xxxxxxxxx x platnost v xxxxxxx x článkem 34 xxxx. 3 Xxxxxx xxx 1. xxxxx 2008 x xxxxx xxxx vstoupila x xxxxxxxx i xxx Xxxxxx xxxxxxxxx. Dnem xxxxxx Xxxxxxx X x xxxxxxxx přestává xxxxxx Příloha X Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx xxxxxx xx xxxxx pro xxx 2007, xxxxxxxxx xxx x. 59/2007 Xx. m. x.

Xxxxxxxx xxxxx Přílohy X a xxxx xxxxxxx xx xxxxxxx xxxxxx xx xxxxxxxxx xxxxxxxx.

X1. ANABOLICKÉ LÁTKY

Xxxxxxxxxx xxxxx xxxx xxxxxxxx.

1. XXXXXXXXXX XXXXXXXXXX XXXXXXXX (XXX):

x. Xxxxxxxx * XXX, xxxxxxxxxx:

1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3β,17β-xxxx); 1-androstendion (5α-xxxxxxx-1-xx-3,17-xxxx); xxxxxxxxx (19-xxxxxxxxxxxxxxxx); xxxxxxxxxx; xxxxxxxx; xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx); xxxxxxx (17α-xxxxxxx-17β-xxxxxxxxxxxxxx-4-xxx[2,3-x]xxxxxxxx); xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx-17β-xxxxxxx-17α-xxxxxxxxxxxxx-1,4-xxxx-3-xx); desoxymethyltestosteron (17α-metyl-5α-androst-2-en-17β-ol); xxxxxxxxxxx; ethylestrenol (19-nor-17α-pregn-4-en-17-ol); xxxxxxxxxxxxxx; xxxxxxxxxx; xxxxxxxxx (17β-xxxxxxx-17α-xxxxx-5α-xxxxxxxxxx[2,3-x]-xxxxxxx); xxxxxxxxx; 4-hydroxytestosteron (4,17β-xxxxxxxxxxxxxxxx-4-xx-3-xx); xxxxxxxxxx; xxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxxxx-1,4-xxxx-3-xx); xxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx (2α, 17α-xxxxxxx-5α-xxxxxxxxx-3-xx-17β-xx); xxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4,9-xxxx-3-xx); methyl-1-testosteron (17β-xxxxxxx-17α-xxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxx-4-xx-3-xx); xxxxxxxxxxxxxxx (17β-hydroxy-17α-metylestra-4,9,11-trien-3-on); xxxxxxxxxxxxxxxxx; xxxxxxxxx; xxxxxxxxx; 19-norandrostendion (xxxx-4-xx-3,17-xxxx); norboleton; xxxxxxxxxxxxxx; xxxxxxxxxxxx; oxabolon; xxxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx ([3,2-x]xxxxxxx-5α-xxxxxxxxxxxxxx-17β-xxxxxxxxxxxxxxxxx); xxxxxxxxx; xxxxxxxxxx; xxxxxxxxx; 1-xxxxxxxxxxx (17β-hydroxy-5α-androst-1-en-3-on); xxxxxxxxxxxxxxxxxxx (18α-xxxx-xxxxxx-4,9,11-xxxxx-17β-xx-3-xx); xxxxxxxxx x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx xxxxxx.

x. Xxxxxxxxx ** XXX:

Xxxxxxxxxxxxx (xxxxxxx-5-xx-3β,17β-xxxx), xxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx), xxxxxxxxxxxxxxxxxx, prasteron (xxxxxxxxxxxxxxxxxxxxx, XXXX), xxxxxxxxxxx x následující xxxxxxxxxx x xxxxxxx:

5α-androstan-3α,17α-diol androst-5-en-3β,17α-diol

5α-xxxxxxxxx-3α,17β-xxxx 4-xxxxxxxxxxxxx (androst-4-en-3β,17β-diol)

5α-xxxxxxxxx-3β,17α-xxxx 5-xxxxxxxxxxxxx (xxxxxxx-5-xx-3,17-xxxx)

5α-xxxxxxxxx-3β,17β-xxxx xxx-xxxxxxxxxxxxxxxxxx

xxxxxxx-4-xx-3α,17α-xxxx 3α-xxxxxxx-5αxxxxxxxxx-17-xx

xxxxxxx-4-xx-3α,17β-xxxx 3β-xxxxxxx-5αxxxxxxxxx-17-xx

androst-5-en-3β,17α-diol 19-norandrosteron

androst-5-en-3α,17α-diol 19-noretiocholanolon

androst-5-en-3α,17β-diol

X xxxxxxxxx, xxx může xxxx xxxxxxxxxx xxxxxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxxx, xxxx se mít xx xx, xx Xxxxxx xxxxxxxx xxxx Xxxxxxxxx látku x xxxx xxxxxx xxxxxxxxx Xxxxxxxxx laboratorní xxxxx, xxxx xx xxxxxxxxxxx Xxxxxxxx xxxxx nebo xxxxxx xxxxxxxxxx xxxx xxxxxxxxxxx x/xxxx když xx xxxxxxxx xxxx xxxxxxxxx xxxxx ve Xxxxxx Xxxxxxxxx xxxxxxxx xxxxxxxxx xx xxxxxxx xxxxxx, xxxxx xx xxxxxxxx vyskytují x xxxx xxx, že xxxxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxx. Nebude xx xxx xx to, xx Vzorek xxxxxxxx Xxxxxxxxx látku v xxxxxxx případě, xxxxx Xxxxxxxxx xxxxxxx, že xx koncentrace Zakázané xxxxx xxxx xxxxxx xxxxxxxxxx xxxx xxxxxxxxxx x/xxxx xxxxxxxxx xxxxx xx Xxxxxx Xxxxxxxxx xxxxxxxx xxxxxxxxxxxxx nebo xxxxxxxxxxxx xxxxxx.

Bude xx mít za xx, xx Xxxxxx Xxxxxxxxx xxxxxxxx Xxxxxxxxx xxxxx x xxxxxxxxx xxxxxxx Xxxxxxxxx xxxxxxxxxxx xxxxx ve xxxxx xxxxxxxxx x při xxxxxxxxx koncentraci, pokud xxx xxxxx xxxxxxxxxx xxxxxxxxxx xxxxxx (xxxx. XXXX) prokázat, xx xx Xxxxxxxx látka xxxxxxxxxx xxxxxx. X xxxxxxx případě není xxxxx xxxxxxxx xxxxx xxxxxxx.

Xxxx se xxxxxxx xxxxxxxx xxxxxxx xxxxxxxx neodchylují xx xxxxxxx xxxxxx, které xx xxxxxxxx vyskytují x xxxx a xxxxx spolehlivá xxxxxxxxxx xxxxxx (xxxx. XXXX) xxxxxxxxxxx xxxxxxxx xxxxx Xxxxxxxx xxxxx, ale xxxxxxxx xxxxxx použití Xxxxxxxx xxxxx, xxxx xxxx. xxxxxxxxx s xxxxxxxxxxx referenčními xxxxxxxxxxx xxxxxxx, xxxx xxxx xxxxxxxxx nahlásila xxxxx X/X xxxxx než xxxxx (4) xx xxxxx (1) x xxxxx xxxxxxxxxx xxxxxxxxxx xxxxxx (xxxx. XXXX) xxxxxxxxxxx exogenní xxxxx xxxxx, xxxxxxx příslušná Xxxxxxxxxxxxx xxxxxxxxxx xxxxx xxxxxxx xxxxxxxxxx výsledků xxxxxxxxxx xxxxx nebo xxxxxxxxxx xxxxxxxxxx xxxxx.

Xx-xx xxxxxxxxxx xxxxxx xxxxx xxxxxxx, xxx xxxxxxxx bude xxxxxxxxxx xxxxxx xxxx neobvyklý x xx xxxx xxxxxxxxx. Xxxxx xxxxxxxxx xxxxxxx, xx xxxxxxx xxxxxxxxxx xxxxxxxxxx metody (xxxx. IRMS) xxxxxxxx xxxxx Xxxxxxxx xxxxx, xxxx xxxxx provádět xxxxx xxxxxxx, x xxxx se xxx xx xx, xx Xxxxxx xxxxxxxx Zakázanou xxxxx. Xxxxx xxxxxx xxxxxxx xxxxxxxxxx analytická xxxxxx (xxxx. XXXX) x xxxxxx k xxxxxxxxx minimálně 3 xxxxxxxxx testy, bude xxxxxxx longitudinální xxxxxx Xxxxxxxxx xxx, že xxxx xxxxxxxxxx Xxxxxxxxxxxxxx xxxxxxxxxx x následujících 3 xxxxxxxx třikrát xxxxxxxx xxx xxxxxxxxxxx xxxxxxxx. Xxxxxxxx, který xxxxxxxxxx tuto longitudinální xxxxxx, xxxx hlášen xxxx neobvyklý. Xxxxx xxxxxxxxxxxxxx profil Xxxxxxxxx, xxxxxxxx xxxxxxxxxx xxxxx, xxxx xxxxxxxxxxxx xxxxxxxx, xxxx se xxx xxxxxxxxx xx Xxxxxxxxx xxxxxxxxxxx nález.

V xxxxxxxx xxxxxxxx individuálních xxxxxxxxx může být x xxxx xxxxxx xxxxxxx boldenon endogenního xxxxxx ve velice xxxxxx xxxxxxxxxxxxx (xx/xx). Xxxxx xxxxxxxxx xxxxxx xxxxx xxxxxxxxx x xxxxxxx spolehlivé analytické xxxxxx (xxxx. XXXX) xxxxxxxxxxx xxxxxxxx původ Xxxxxxxx xxxxx, xxxx xxx provedeno další xxxxxxx xxxxxxxxxx xxxxxxxxxx xxxxx (xxxxxxxxxx xxxxx).

Xxxxx xxxxxxxxx xxxxxxxxx Xxxxxxxxx xxxxxxxxxxx xxxxx 19-xxxxxxxxxxxxxxx, xxxx xx xx xxxxxxxxx xx xxxxxxx a xxxxxxxxxxx xxxxx xxxxxxxxxx xxxxxx Xxxxxxxx xxxxx. X xxxxxxx xxxxxxx xxxx xxxxx provádět další xxxxxxx.

V xxxxxxx, xx Sportovec xxxxxx xxxxxxxxxxxxx při xxxxxxx xxxxxxxxx, xxxx xx xxx xx to, xx Xxxxxx Sportovce xxxxxxxx Xxxxxxxxx xxxxx.

2. Ostatní xxxxxxxxxx xxxxx, zahrnující:

Xxxxxxxxxxx, xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (SARM), xxxxxxx, xxxxxxx, xxxxxxxxxx, xxx xx s xxxxxxxx xxxxx xx xx.

S2. XXXXXXX A XXXXXXXX XXXXX

Xxxxxxxxxxx xxxxx x xxxxxx xxxxxxxxxx xxxxxxx xxxx xxxxxxxx:

1. Xxxxxxxxxxxx (EPO);

2. Xxxxxxx xxxxxx (xXX), insulinu xxxxxxx xxxxxxx faktory (např. XXX-1), xxxxxxxxxx xxxxxxx xxxxxxx (XXX);

3. Xxxxxxxxxxxxx (např. XX, xXX), xxxxxxxx xxx x mužů;

4. Xxxxxxxx;

5. Xxxxxxxxxxxxxx

x xxxxx látky x xxxxxxxx xxxxxxxxx xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx xxxxxx.

Xxxxx Xxxxxxxxx nemůže prokázat, xx xxxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxxx xx xxxxxxxxxxxx xxxxxx, xxxx xx mít xx xx, xx Vzorek xxxxxxxx Xxxxxxxxx xxxxx (xxx xx xxxxxxx xxxx) x xxxxxxxxx, xxx xxxxxxxxxxx Xxxxxxxx xxxxx xxxx jejích xxxxxxxxxx či indikátorů x/xxxx xxxxxxxxx xxxxxx xx Xxxxxx Xxxxxxxxx xxxxxxx překročí xxxxxxx xxxxxxxx xxxxxxxx u xxxx xxx, že xxxxxxxxxxxx normální xxxxxxxxx xxxxxxxx.

Xxxxx xxxxxxxxx xxxxxxxxx, xx xxxxx xxxxxxxxxx xxxxxxxxxx metody, xx Xxxxxxxx xxxxx xx xxxxxxxxxx xxxxxx, xxxx se xxx xx xx, xx Xxxxxx obsahuje Xxxxxxxxx xxxxx a xxxx xxxxxxx Xxxxxxxxx laboratorní xxxxx.

X3. XXXX-2 XXXXXXXX

Xxxxxxx xxxx-2 xxxxxxxx xxxxxx xxxxxx D- x X-xxxxxxx xxxx zakázáni.

Xxxxxxxx jsou xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx x xxxxxxxxxx, xxx které xx při inhalaci xxxxx xxxxxxx xxxxxxxx xxxxxxxxxxxx xxxxxxx.

X xxxx xxxx xxxxxxx xxxxxxxx xxxxx terapeutické xxxxxxx, bude nález xxxxxxxxxxx (xxxxx xxxx xxxxxxxxxx) xxxxx xxx 1000 xxxxxxxxx v 1 xxxxxxxxx xxxx xxxxxxxxx xx Xxxxxxxxx xxxxxxxxxxx nález, xxxxx Xxxxxxxxx xxxxxxxxx, že xxxxxxxxxx xxxxxxxx xxx xxxxxxxx terapeutickým užíváním xxxxxxxxxxx x inhalaci.

S4. XXXXXXXXXXX X XXXXXXXXXX XXXXXXX

Xxxxxxxxxxx xxxxxxx jsou xxxxxxxx:

1. Xxxxxxxxxx xxxxxxxx, xxxxxxxxxx:

2. Selektivní modulátory xxxxxxxxxxxxx xxxxxxxxx (SERM), xxxxxxxx:

3. Xxxxxxx antiestrogenní látky xxxxxxxxxx:

4. Xxxxx modifikující funkce xxxxxxxxxx xxxxxx xxxxxxxxxx xxxxxxxxxx, xxx ne x omezením xxxxx xx ně.

X5. XXXXXXXXX X XXXXXXX XXXXXXXXX LÁTKY

Xxxxxxxxx látky xxxx xxxxxxxx. Xxxxxxxx:

Xxxxxxxxx*, xxxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx alfa-reduktázy (xxxx. xxxxxxxxxx, xxxxxxxxxx), plasmaexpandery (xxxx. xxxxxxx, xxxxxxx, xxxxxxxxxxxxxxxxx) x xxxxx xxxxx x podobnými xxxxxxxxxxxx účinky.

Xxxxxxxxx xxxxxxxx:

Xxxxxxxxxxxx, amilorid, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxx, xxxxxxxx, xxxxxxxx xxxxxxxxxx, metolazon, xxxxxxxxxxxxx, xxxxxxxx (xxxx. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx), triamteren x další xxxxx x podobnou xxxxxxxxx xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx xxxxxx (xxxxx xxxxxxxxxxxx, který není xxxxxxxx).

* Terapeutická xxxxxxx xxxx xxxxxx, xxxxx xxx Xxxxxxxxx xxxxxxxx diuretika xx xxxxxxx s xxxxxxxx xxxx podprahovou xxxxxxxx xxxx Zakázané xxxxx (xxxxx).

X1. XXXXXXXXX PŘENOSU XXXXXXX

Xxxxxxxx je xxxxxxxxxxx:

X2. CHEMICKÁ X FYZIKÁLNÍ XXXXXXXXXX

M3. XXXXXX XXXXXX

Neterapeutické xxxxxxx buněk, xxxx, xxxxxxxx xxxxxxxx, nebo xxxxxxxxxx exprese xxxx, xxxxx xxxx schopnost xxxxxx xxxxxxxxx xxxxx, xx xxxxxxxx.

X6. STIMULANCIA

Xxxxxxx xxxxxxxxxxx (xxxxxx xxxx xxxxxx xxxxxxxxxx xxxxxxxxx (X- x X-) xxxxxxx) xxxx zakázaná, x xxxxxxxx xxxxxxxx xxxxxxxxx v xxxxxxx xxxxxx xxxxxxxx xxxxx x stimulancií xxxxxxxxxx xx Xxxxxxxxxxxxxx programu xxx rok 2008.

Xxxxxxxxxxx xxxxxxxx:

Adrafinil, xxxxxxxxx**, xxxxxxxxxx, amfetaminil, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxxx****, etamivan, xxxxxxxxx, ethylamfetamin, famprofazon, xxxxxxxxxxx, fendimetrazin, xxxxxxxxx, xxxxxxxxxxx, fenkamfamin, fenkamin, xxxxxxxxxxx, xxxxxxxxxxxxx, fenproporex, xxxxxxxxx, 4-xxxxxxxxxxxxxx (karfedon), xxxxxxxxxx, xxxxxxxxxx, isomethepten, xxxxx***, klobenzorex, xxxxxx, xxxxxxxxxxx, krotetamid, xxxxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxx (X-), metylefedrin****, xxxxxxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxx, parahydroxyamfetamin, xxxxxxx, pentetrazol, p-methylamfetamin, xxxxxxxxx, propylhexedrin, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxx x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.

Xxxxxxxxxxxx xxxxxxxxx xxxxxxxx xxxx xxxxxxxx x xxxxx xxxxxx bude xxxxxxxxxx za xxxxxxxxxxx xxxxx xxxxx, xxxxx Xxxxxxxxx xxxxxxx, xx xxxx xxxxxxxxx xxxxxxxxxx x běžných xxxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxxxxxxxxxx pravidel, xxxx xx x xxx xxxxx xxxxxxxxxxxxxxx, xx bude xxxxxxx xxxxxxxx xxxx dopingová xxxxx.

X7. XXXXXXXXX

Xxxxxxxxxxx narkotika xxxx zakázaná:

Xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxx(xxxxxx), xxxxxxxx x xxxx xxxxxxxx, xxxxxxxxxxx, xxxxxxx, xxxxxx, xxxxxxxx, oxymorfon, xxxxxxxxxx, xxxxxxx.

X8. XXXXXXXXXXX

Kanabinoidy (xxxx. xxxxx, marihuana) jsou xxxxxxxx.

S9. XXXXXXXXXXXXXXXXXXXX

Xxxxxxx glukokortikosteroidy xxxxxxxx xxxxxx, xxxxxxxx, xxxxxxxxxx xxxx nitrosvalovou xxxxxxxx xxxx xxxxxxxx. Xxxxxx xxxxx vyžaduje xxxxxxxxxxxxx výjimku.

Xxxx xxxxxxx xxxxxxxx xxxxxxxx (xxxxxxxxxxxx, xx xxxxx xxxxxx, xx xxxxx xxxxxx, epidurální, xx xxxx) a xxxxxxxxx xxxxxxxx xxxxxxxx zkrácenou xxxxxxxxxxxxx výjimku x xxxxxxxx xxxx xxxxxxxxx.

Xxxxxxx xxxxxxxxx xxxxxxxx xx xxxxxx xxxxx (xxxxxx xxxxxxxxxxx/xxxxxxxxxx), ušní, xxxxx, xxxx, potíže xxxxx řitního xxxxxx, xxxxxxxx úst x xxxxx nejsou xxxxxxxx x xxxxxxxxxx žádnou xxxxx xxxxxxxxxxxx xxxxxxx.

P1. XXXXXXX

Xxxxxxx (etanol) xx xxxxxxxx xxxxx Xxx soutěži x xxxxxxxxxxxxx xxxxxxxx. Detekce xx xxxx provádět xxxxxxxx xxxxxxxx x/xxxx xxxxxxxx krve. Xxxxxxx xxxxxxx pro xxxxxxxx xxxxxxxxxxx xxxxxxxx (hematologická xxxxxxx) xx xxx xxxxxx federaci xxxxxxx x xxxxxxxxx.

∙ Xxxxxxxxxxxx xxxxx (FIA) (0.10 x/x)

∙ Xxxxxx (XXX) (0.10 x/x)

∙ Xxxxxxx xxxxxx x xxxxxxxxxxxx (XXX) (0.20 x/x)

∙ Xxxxxxxxxxx (FITA, XXX) (0.10 x/x)

∙ Moderní xxxxxxx (XXXX) xxx xxx xxxxxxxxxx xx xxxxxxxx (0.10 g/l)

∙ Xxxxxxxxxxx xxxxx (XXX) (0.10 g/l)

∙ Vodní xxxxxxxxxx (XXX) (0.30 g/l)

∙ Kuželky (XXX) (0.10 x/x)

X2. BETA-BLOKÁTORY

Pokud xxxx xxxxx xxxxxx, xxxx-xxxxxxxxx xxxx xxxxxxxx xxxxx Xxx soutěži x následujících sportech.

∙ Automobilový sport (XXX)

∙ Billiard (XXXX)

∙ Xxxx (XXXX)

∙ Bridž (XXX)

∙ Xxxxxxx (XXX)

∙ Gymnastika (XXX)

∙ Xxxxxxxx (XXXX) - "match xxxx" - xxx xxxxxxxxxxx

∙ Kuželky (XXX)

∙ Xxxxxxx xxxxxx x xxxxxxxxxxxx (XXX)

∙ Xxxxxxxxxxx (XXXX, XXX) (xxxxxxxx xxxx Mimo soutěž)

∙ Xxxxxxxx (XXX) - skoky xx xxxxxx x xxxxxxxxxxx xxxxxxxx-xxxxx a X-xxxxx, x xxxxxxxxx X-xxxxx x "big air"

∙ Xxxxxxx pětiboj (XXXX) - xxx xxxxxxxxxx se xxxxxxxx

∙ Motocyklový xxxxx (XXX)

∙ Xxxxxxxx x xxxxxxx xxxxxx (XXXX, XXX "xxxxx")

∙ Střelba (XXXX, XXX) (xxxxxxxx také Xxxx xxxxxx)

∙ Xxxxx xxxxxxxxxx (XXX)

∙ Xxxxx (XXXX)

Xxxx-xxxxxxxxx zahrnují xxxxxxxxxxx xxxxx:

Xxxxxxxxxx, xxxxxxxxxx, xxxxxxxx, betaxolol, xxxxxxxxxx, xxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxx, xxxxxxxxxx, labetalol, xxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxx, oxprenolol, xxxxxxxx, xxxxxxxxxxx, xxxxxxx, timolol, xxx xx x xxxxxxxx pouze xx xx

"Specifické xxxxx"* xxxx xxxxxxxxxxx xxxx:

∙ Xxxxxxx Xxxx-2 xxxxxxxx x xxxxxxxx, xxxxx xxxxxxxxxxx (xxxxxxx xxxx glukuronidu) xxx xxxxxxxx xxxxxx xxx 1000 xx/xx moči x clenbuterolu (zařazen xx skupině X 1.2 Xxxxxxx anabolické xxxxx);

∙ Xxxxxxxxxx xxxx-xxxxxxxxx, xxxxxxxxxx;

∙ Xxxxx, xxxxxxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxxxxx, meklofenoxát, x-xxxxxxxxxxxxxx, xxxxxxxxxxxx, niketamid, xxxxxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxx x xxxxxxx xxxxxxx xxxxxxxxxxx neuvedená xxxxxxxx x xxxxxx X6, xxx xxxxx Xxxxxxxxx xxxxxxx, xx xxxxxxx xxxxxxxx xxxxxxx x xxxxxx S6;

∙ Kanabinoidy;

∙ Xxxxxxx Xxxxxxxxxxxxxxxxxxxx;

∙ Xxxxxxx;

∙ Xxxxxxx Xxxx-xxxxxxxxx.

*"X Xxxxxxx xxxxx xxx vyjmenovány xxxxxxxxxx xxxxx, které xxxxxxxx umožňuji neúmyslné xxxxxxxx antidopingových xxxxxxxx, xxxxxxx xxxx všeobecně xxxxxxxx x xxxxxxx xxxxxxxxx přípravcích, nebo x nichž je xxxxx xxxxxxxxxxxxxxx, xx xxxxx xxxxxxx zneužity xxxx xxxxxxxxx xxxxxxx." Xxxxxxxx xxxxxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx xxxxx xxxx znamenat xxxxxxx xxxxxx za xxxxxxxxxxx, xx "...Sportovec může xxxxx prokázat, že Xxxxxxx xxxxxxxxxx látky xxxxxx xxxxxxxxx ke xxxxxxx xxxxxxxxxxx xxxxxx...".

Xxxxxx předpis č. 2/2008 Sb. x. x. nabyl xxxxxxxxx xxxx 31.1.2008.

Xxxxxx xxxxxxx č. 2/2008 Xx. x. x. xxx zrušen xxxxxxx xxxxxxxxx č. 8/2009 Sb. m. s. x xxxxxxxxx od 7.2.2009.

Xxxxx xxxxxxxxxxxx právních xxxxx xxxxxx právních xxxxxxxx x xxxxxxxx xxxx xxxxxxxxxxxxx, xxxxx xx xxxx xxxxxx xxxxxxxxx xxxxx shora xxxxxxxxx xxxxxxxx xxxxxxxx.